Myocardial GRK2 Reduces Fatty Acid Metabolism and β-Adrenergic Receptor-Mediated Mitochondrial Responses

Ruxu Zhai1, Erika L Varner2, Ajay Rao2,3

  • 1Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA 19102, USA.

Insights

Upregulated G-protein coupled receptor kinase 2 (GRK2) in heart failure impairs mitochondrial function and fatty acid metabolism. This suggests GRK2 is a key player in cardiac bioenergetic remodeling and a potential therapeutic target.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Mitochondrial Biology

Background:

  • G-protein coupled receptor kinase 2 (GRK2) is elevated in heart failure (HF).
  • GRK2 regulates β-adrenergic receptors (βARs) and is found in mitochondria, but its metabolic role is unclear.
  • GRK2 upregulation is hypothesized to impair mitochondrial respiration and βAR signaling.

Purpose of the Study:

  • To investigate the role of GRK2 in mitochondrial function and metabolism in cardiac cells.
  • To determine if GRK2 impacts cell survival under different metabolic conditions.
  • To assess the effect of GRK2 on mitochondrial responses to βAR activation.

Main Methods:

  • Isolated mouse primary adult cardiomyocytes (ACMs) were used.
  • Experiments involved various substrates (glucose, palmitate, ketone bodies, BCAAs) and βAR agonist (isoproterenol).
  • Isotopologue labeling and mass spectrometry analyzed metabolic pathways.

Main Results:

  • GRK2 upregulation promoted palmitate-induced cell death in myocytes.
  • GRK2 reduced β-hydroxybutyryl CoA generation and impaired fatty acid catabolism.
  • GRK2 upregulation impaired isoproterenol-stimulated mitochondrial function in mouse and human ACMs.

Conclusions:

  • Cardiac GRK2 upregulation disrupts mitochondrial function and fatty acid metabolism.
  • GRK2 plays a role in cardiac bioenergetic remodeling during pathological conditions.
  • GRK2 represents a potential therapeutic target for heart failure.

Related Concept Videos

G-Protein Gated Ion Channels01:21

G-Protein Gated Ion Channels

GPCRs are primarily responsible for our sense of smell, taste, and vision.  The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory...
4.9K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
2.6K
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.0K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
949
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
543